Immunotherapy for non-Hodgkin's lymphoma

Current Opinion in Oncology

Volumn 8, Issue 5, 1996, Pages 353-359

  Longo, Dan L ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; CD20 ANTIGEN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOTOXIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; RITUXIMAB; SOMATOSTATIN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN PRESENTING CELL; CANCER REGRESSION; CANCER SURVIVAL; CELL DEATH; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EPSTEIN BARR VIRUS; FOLLICULAR LYMPHOMA; IMMUNE RESPONSE; IMMUNOTHERAPY; MALIGNANT TRANSFORMATION; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW;

EID: 0029861524     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199609000-00003     Document Type: Review

References (46)

1. Solal-Celigny P, Lepage E, Brousse N, et al.: Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 1993, 329:1608-1614.
2. Solal-Celigny P: GELF studies of intron A in follicular lymphomas: an update on the clinical data [abstract]. Ann Oncol 1996. 7 (suppl 3):229
3. Vander Molen LA, Steis RG, Duffey PL, et al.: Low-versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma. J Natl Cancer Inst 1990, 82:235-238.
4. Soiffer RJ, Murray C, Gonin R, Ritz J: Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 1994, 84:964-971.
5. De Laurenzi A, Iudicone P, Zoli V, el al.: Recombinant interleukin-1 treatment before and after autologous stem cell transplantation in hematologic malignancies: clinical and immunologic effects. J Hematother 1995, 4:113-120.
6. Raspadori D, Lauria F, Ventura MA, et al.: Low doses of rIL2 after autologous bone marrow transplantation induce a "prolonged" immunostimulation of NK compartment in high-grade non-Hodgkin's lymphomas. Ann Hematol 1995, 71:175-179.
7. Federico M, Gobbi PG, Moretti G, et al.: Effects of thymostimulin with combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma: a report from the Italian Lymphoma Study Group (GISL). Am J Clin Oncol 1995, 18:8-14.
8. Rettenbacher L, Galvan G: Differentiation between residual cancer and thymic hyperplasla in malignant non-Hodgkin's lymphoma with somatostatin receptor sclntigraphy. Clin Nucl Med 1994, 19:64-65.
9. Witzig TE, Letendre L, Gerstner J, et al.: Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial. J Clin Oncol 1995, 13:2012-2015.
10. Nadler LM, Stashenko P, Hardy R, et al.: Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980, 40:3137-3154.
11. McLaughlin P, Grillo-Lopez AJ, Czuczman M, et al.: Pivotal phase III clinical trial of the chimeric anti-CD20 antibody IDEC-C2B8 in patients with relapsed low-grade or follicular lymphoma: a preliminary report [abstract]. Ann Oncol 1996, 7 (suppl 3):57
12. Czuczman MS, Grillo-Lopez AJ, Jonas C, et al.: IDEC-C2B8 and CHOP chemotherapy of low grade lymphoma [abstract]. Blood 1995, 86 (suppl):55a.
13. Grillo-Lopez AJ, Chinn P, Morena R, et al.: Treatment of relapsed non-Hodgkin's lymphoma using the 90-yttrium labeled anti-CD20 monoclonal antibody IDEC-Y2B8: a phase I clinical trial [abstract]. Ann Oncol 1996, 7 (suppl 3):57.
14. Uppenkamp M, Hoffkes H.G, Meusers P, et al.: Monoclonal antibody therapy with "CAMPATH-1H" in relapsed non-Hodgkin's lymphomas: a phase I/II study in Germany [abstract]. Ann Oncol 1996, 7 (suppl 3):150.
15. Hutchins JT, Kull FC Jr, Bynum J, et al.: Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a γ4 variant of Campath-1H. Proc Natl Acad Sci U S A 1995, 92:11980-11984.
16. DeGast GC, Haagen I-A, van Houten AA, et al.: CD8 T cell activation after intravenous administration of CD3XCD19 bispecific antibody in patients with non-Hodgkin's lymphoma. Cancer Immunol Immunother 1995, 40:390-396.
17. Grossbard ML, Fidias P: Prospects for immunotoxin therapy of non-Hodgkin's lymphoma. Clin Immunol Immunopathol 1995, 76:107-114. This is a well-written, balanced review of the theoretical potential of immunotoxins, the results of clinical trials to date, the problems encountered, and proposed approaches to solving the problems.
18. Yazdi PT, Wenning LA, Murphy RM: Influence of cellular trafficking on protein synthesis inhibition of immunotoxins directed against the transferrin receptor. Cancer Res 1995, 55:3763-3771.
19. Flavell DJ, Flavell SU, Boehm DA, et al.: Preclinical studies with the anti-CD19-saporin immunotoxin BU12-saporin for the treatment of human B-cell tumors. Br J Cancer 1995, 72:1373-1379.
20. Flavell DJ, Boehm DA, Emery L, et al.: Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone. Int J Cancer 1995, 62:337-344.
21. French RR, Penney CA, Browning AC, et al: Delivery of the rlbosome-inactivating protein, gelonln, to lymphoma cells via CD22 and CD38 using bispecific antibodies. Br J Cancer 1995, 71:986-994.
22. + anaplastic large cell lymphoma. Blood 1995, 85:2139-2146.
23. O'Connor R, Liu C, Ferris CA, et al.: Anti B4-blocked ricin synergized with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood 1995, 86:4286-4294.
24. Jurcic JG, Scheinberg DA: Radioimmunotherapy of hematological cancer: problems and progress. Clin Cancer Res 1995, 1:1439-1446. This is an objective and scholarly review of the potential, the problems, and the prospects of targeted delivery of radionuclides in hematologic malignancy.
25. Wilder RB, DeNardo GL, DeNardo SJ: Radioimmunotherapy: recent results and future directions. J Clin Oncol 1996, 14:1383-1400. Also a good review, this paper is written from the point of view of advocating radioimmunoconjugate therapy.
26. Press OW, Eary JF, Appelbaum FR, et al: Phase II trial of 131-I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995, 346:336-340. This is a seminal study in radioimmunotherapy. It appears that there is considerable efficacy for iodine-labeled anti-CD20 given at myeloablative doses. The incorporation of this agent into multiagent preparative regimens is a promising avenue for further clinical development.
27. Kaminski MS, Fenner MC, Estes J, et al.: Phase I/II trial results of 131-I-anti-B1 (anti-CD20) non-myeloablative radioimmunotherapy for refractory B-cell lymphoma [abstract]. Proc Am Soc Clin Oncol 1996, 15:414.
28. Press OW, Shan D, Howell-Clark J, et al.: Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996, 56:2123-2129. These experiments suggest that microcurie for microcurie, yttrium isotopes should do more damage to cells than iodine isotopes.
29. 90Y-anti-CD20 monoclonal antibody therapy for recurrent B cell lymphoma [abstract]. Int J Radiat Oncol Biol Phys 1995, 32:215.
30. White CA, Halpern SE, Parker BA, et al: Radioimmunotherapy of relapsed B-cell lymphoma with yttrium-90 anti-idiotype monoclonal antibodies. Blood 1996, 87:3640-3649.
31. Hsu FJ, Caspar CB, Czerwinski D, et al.: Active idiotype vaccination following chemotherapy induces a specific anti-tumor immune response and prolongs remission in patients with non-Hodgkin's lymphoma [abstract]. Ann Oncol 1996, 7 (suppl 3):19.
32. Nelson EL, Li X, Hsu FJ, et al.: Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 1996, 88:580-589. This paper presents a careful analysis of the influence of idiotype vaccination on the precursor frequency of circulating cytotoxic T cells capable of mounting a tumor-specific response. Maximizing the T-cell response is a goal of physicians developing vaccines.
33. Hsu FJ, Benike C, Fagnoni F, et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996, 2:52-58. This paper demonstrates impressive immune responses to antigens presented by autologous antigen-pulsed dendritic cells, a finding that may be of general applicability in the development of cancer vaccines.
34. Foon KA, Oseroff AR, Vaickus L, et al.: Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen. Clin Cancer Res 1995, 1:1285-1294.
35. Schultze J, Cardoso A, Boussiotis V, et al.: Generation of anti-follicular lymphoma specific T cell mediated immunity [abstract]. Ann Oncol 1996, 7 (suppl 3):19
36. Papadopoulos EB, Ladanyi M, Emanuel D, et al.: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994, 330:1185-1191.
37. Walter EA, Greenberg PD, Gilbert MJ, et al.: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995, 333:1038-1044. The ability to expand large numbers of antigen-specific T cells from a bone marrow donor and have them function in the recipient is a fundamental advance in the field of adoptive immunotherapy.
38. Riddell SR, Greenberg PD: Cellular adoptive immunotherapy after bone marrow transplantation. Cancer Treat Res 1995, 76:337-369.
39. Lacerda JF, Ladanyi M, Louie DC, et al.: Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B-cell lymphoproliferations in xenografted CB-17 scid/scid mice. J Exp Med 1996, 183:1215-1228.
40. Kwak LW, Taub DD, Duffey PL, et al.: Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995, 345:1016-1020.
41. Smith MR, Abubakr Y, Mohammad R, et al.: Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL Cancer Gene Ther 1995, 2:207-212.
42. Cotter FE, Corbo M, Raynaud F, et al.: Bcl-2 antisense therapy in lymphoma: in vitro and in vivo mechanisms, efficacy, pharmacokinetic, and toxicity studies [abstract]. Ann Oncol 1996, 7 (suppl 3):32.
43. Webb A, Cunningham D, Cotter F, et al.: Phase I antisense trial: preliminary results [abstract]. Ann Oncol 1996, 7 (suppl 3):32.
44. Renschler MF, Wada HG, Fok KS, Levy R: B-lymphoma cells are activated by peptide ligands of the antigen binding receptor or by antiidiotypic antibody to induce extracellular acidification. Cancer Res 1995, 55:5642-5647.
45. Murphy WJ, Funakoshi S, Beckwith M, et al.: Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes. Blood 1995, 86:1946-1953.
46. Tian Z-G, Longo DL, Funakoshi S, et al.: In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res 1995, 55:5335-5341.